{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for clindamycin root_Display\ Name in Display Name (approximate match)
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Xantofyl palmitate (brand name Adaptinol) is an approved drug for retinitis pigmentosa in Japan since August 1956. Adaptinol promotes aerobic metabolism of the retina to expand visual field or delay the development of narrowing of visual field. It also acts on the retina to improve vision in the dark.
It is usually used to transiently improve visual field and dark adaptation in patients with retinitis pigmentosa.
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M020
(2012)
Source URL:
First approved in 2000
Source:
ANDA040246
Source URL:
Class:
MIXTURE
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
